Standard
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. / Nielsen, S E; Schjoedt, K J; Astrup, A S; Tarnow, Lise; Lajer, Marianne; Hansen, P R; Parving, H-H; Rossing, Pia.
I:
Diabetic Medicine, Bind 27, Nr. 10, 01.10.2010, s. 1144-50.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Nielsen, SE, Schjoedt, KJ, Astrup, AS, Tarnow, L, Lajer, M
, Hansen, PR, Parving, H-H & Rossing, P 2010, '
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril',
Diabetic Medicine, bind 27, nr. 10, s. 1144-50.
https://doi.org/10.1111/j.1464-5491.2010.03083.xAPA
Nielsen, S. E., Schjoedt, K. J., Astrup, A. S., Tarnow, L., Lajer, M.
, Hansen, P. R., Parving, H-H., & Rossing, P. (2010).
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril.
Diabetic Medicine,
27(10), 1144-50.
https://doi.org/10.1111/j.1464-5491.2010.03083.xVancouver
Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, Lajer M
, Hansen PR o.a.
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril.
Diabetic Medicine. 2010 okt. 1;27(10):1144-50.
https://doi.org/10.1111/j.1464-5491.2010.03083.xAuthor
Nielsen, S E ; Schjoedt, K J ; Astrup, A S ; Tarnow, Lise ; Lajer, Marianne ; Hansen, P R ; Parving, H-H ; Rossing, Pia. / Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. I: Diabetic Medicine. 2010 ; Bind 27, Nr. 10. s. 1144-50.
Bibtex
@article{aa9cdfa0ad5a4513b3fb6101aa9a6fd5,
title = "Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril",
abstract = "Our aim was to evaluate the markers of tubulointerstitial damage, neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule1 (KIM1) in Type 1 diabetic patients with different levels of albuminuria and in control subjects. In addition, the effect of renoprotective treatment on urinary NGAL was evaluated in diabetic nephropathy.",
author = "Nielsen, {S E} and Schjoedt, {K J} and Astrup, {A S} and Lise Tarnow and Marianne Lajer and Hansen, {P R} and H-H Parving and Pia Rossing",
note = "{\textcopyright} 2010 The Authors. Diabetic Medicine {\textcopyright} 2010 Diabetes UK.",
year = "2010",
month = oct,
day = "1",
doi = "http://dx.doi.org/10.1111/j.1464-5491.2010.03083.x",
language = "English",
volume = "27",
pages = "1144--50",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "10",
}
RIS
TY - JOUR
T1 - Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril
AU - Nielsen, S E
AU - Schjoedt, K J
AU - Astrup, A S
AU - Tarnow, Lise
AU - Lajer, Marianne
AU - Hansen, P R
AU - Parving, H-H
AU - Rossing, Pia
N1 - © 2010 The Authors. Diabetic Medicine © 2010 Diabetes UK.
PY - 2010/10/1
Y1 - 2010/10/1
N2 - Our aim was to evaluate the markers of tubulointerstitial damage, neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule1 (KIM1) in Type 1 diabetic patients with different levels of albuminuria and in control subjects. In addition, the effect of renoprotective treatment on urinary NGAL was evaluated in diabetic nephropathy.
AB - Our aim was to evaluate the markers of tubulointerstitial damage, neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule1 (KIM1) in Type 1 diabetic patients with different levels of albuminuria and in control subjects. In addition, the effect of renoprotective treatment on urinary NGAL was evaluated in diabetic nephropathy.
U2 - http://dx.doi.org/10.1111/j.1464-5491.2010.03083.x
DO - http://dx.doi.org/10.1111/j.1464-5491.2010.03083.x
M3 - Journal article
VL - 27
SP - 1144
EP - 1150
JO - Diabetic Medicine
JF - Diabetic Medicine
SN - 0742-3071
IS - 10
ER -
